Related Experiment Video
Updated: Mar 3, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Metastatic soft tissue sarcoma: current treatment landscape and future perspectives
E Skafida1, S Kokkali2, M Nikolaou3
1a Department of Internal Medicine, Oncology Unit , University Hospital of Athens , Athens , Greece.
Expert Review of Anticancer Therapy
|April 21, 2017
Summary
Advanced soft tissue sarcoma (STS) treatments are improving, but heterogeneity limits benefits. Tailored therapy, including novel drugs and biological approaches, is crucial for better patient outcomes in advanced STS.
Area of Science:
- Medical Oncology
- Sarcoma Research
Background:
- Advanced soft tissue sarcoma (STS) treatment options have expanded, with doxorubicin as first-line therapy.
- Beyond first-line, no standard treatment exists, and novel drugs show variable efficacy due to STS heterogeneity.
Purpose of the Study:
- To review Phase III clinical trials in unselected advanced STS populations.
- To discuss the impact of recent trials on current clinical practice.
- To consider relevant Phase I-II trials and future therapeutic directions.
Main Methods:
- Systematic review of recent Phase III clinical trials in advanced STS.
- Inclusion of notable Phase I-II trials.
- Analysis of treatment efficacy and impact on clinical management.
Main Results:
- Novel therapies offer benefits to a subset of advanced STS patients, but broad efficacy is limited by disease heterogeneity.
- Current data highlights the need for personalized treatment strategies.
Conclusions:
- Tailoring clinical management for advanced STS patients is essential for optimizing therapy.
- Future research should focus on biological therapies, targeted anti-angiogenesis treatments, and immunotherapy for improved long-term control.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K